alquence recommended for approval in the EU by CHMP for chronic lymphocytic leukaemia
27 July 2020 07:10 BST Calquence recommended for approval in theEU by CHMP for chronic lymphocytic leukaemia Recommendation based on two Phase III trials demonstrating superior progression-free survival across multiple settings while maintaining favourable tolerability AstraZeneca's Calquence (acalabrutinib) has been recommended for marketing authorisation in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.[1] The Committee for Medicinal Products for Human Use (CHMP) of the